Ivermectin and Long COVID: What the Research Actually Shows

Ivermectin is a well-established, FDA-approved medication that has been used safely for decades to treat parasitic infections in both humans and animals. Discovered in the late 1970s, it revolutionized the treatment of conditions like onchocerciasis (river blindness) and strongyloidiasis, earning its discoverers the Nobel Prize in Medicine. In these parasitic contexts, ivermectin works by binding to specific chloride channels in the nervous systems of invertebrates, causing paralysis and death of the parasite. Because human nervous systems are protected by the blood-brain barrier and utilize different receptor structures, the drug is generally very safe when used at standard, approved doses for these specific parasitic indications.

When the COVID-19 pandemic began, researchers urgently screened thousands of existing, FDA-approved drugs to see if any could be repurposed to fight the novel coronavirus. This strategy, known as drug repurposing, is a common and highly efficient way to bypass the decades-long development process of new pharmaceuticals. During these early screening processes, laboratory studies suggested that ivermectin might possess antiviral properties against SARS-CoV-2 in a petri dish. This initial spark of in vitro research ignited widespread hope and led to its rapid adoption by some clinicians and patients before rigorous human trials could be completed.

To understand why ivermectin was proposed for Long COVID, it is essential to understand the underlying mechanisms suspected to drive the condition. One of the leading theories in Long COVID research is the viral persistence hypothesis. This theory suggests that the SARS-CoV-2 virus, or its molecular components like viral RNA and the Spike protein, is not completely cleared by the immune system after the acute infection resolves. Instead, these viral remnants may hide in "immune-privileged" tissue reservoirs, such as the gastrointestinal tract, central nervous system, or cardiovascular system, continuously triggering an immune response. For a deeper dive into how this affects the body, you can read our guide on Understanding Long COVID: Causes, Symptoms, and What the Science Says.

If viral persistence is indeed driving the chronic inflammation and debilitating symptoms of Long COVID, the logical clinical approach is to use antiviral medications to clear these hidden reservoirs. This is why researchers and patients alike have been keenly interested in antiviral therapies, ranging from specialized drugs like Paxlovid to repurposed medications like ivermectin. The hope was that by stopping any lingering viral replication or clearing viral debris, the immune system could finally reset, alleviating symptoms like severe fatigue and post-exertional malaise (PEM). Understanding this rationale is crucial for validating why so many patients sought out these treatments in the first place.

Living with Long COVID often means enduring a profound loss of baseline functioning while navigating a medical system that may lack immediate, definitive answers. Patients frequently experience severe brain fog, debilitating fatigue, and immune dysregulation that drastically alter their quality of life. In the absence of FDA-approved treatments specifically for Long COVID, many individuals understandably turned to alternative or off-label therapies that were being discussed in online support groups and by certain medical practitioners. Ivermectin became a focal point of these discussions due to its low cost, widespread availability, and the early, albeit preliminary, observational reports suggesting it might help.

It is vital to acknowledge the immense frustration and desperation that drives the search for off-label treatments. When you are fighting for your health and your livelihood, waiting years for clinical trial results can feel impossible. The interest in ivermectin was not born out of a disregard for science, but rather a desperate need for relief from relentless symptoms. However, as we will explore in the following sections, the transition from theoretical hope to proven clinical efficacy is a rigorous process, and the scientific consensus on ivermectin has evolved significantly as more robust data has become available.

The initial excitement surrounding ivermectin as a potential COVID-19 treatment was rooted in its theoretical biological mechanisms. When SARS-CoV-2 infects a human cell, it attempts to hijack the host's cellular machinery to replicate and suppress the host's natural antiviral immune response. To do this, viral proteins—specifically the nucleocapsid (N) protein—must enter the nucleus of the host cell. The virus utilizes a specific host transport pathway involving proteins called Importin alpha (IMPα) and Importin beta-1 (IMPβ1) to gain entry into the nucleus. This is a critical step in the virus's ability to evade the immune system and multiply.

Early laboratory studies demonstrated that ivermectin could act as a host-directed agent by binding to the armadillo (ARM) domain of the IMPα protein. By binding to this specific site, ivermectin theoretically prevents IMPα from forming a heterodimer with IMPβ1, effectively blocking the transport of viral proteins into the nucleus. In vitro studies showed that this blockade allowed the host cell's natural antiviral responses to remain intact, significantly reducing viral replication in a controlled laboratory environment. This mechanism provided a highly plausible biological rationale for why ivermectin might work as an antiviral agent against SARS-CoV-2.

Beyond its theoretical antiviral properties, ivermectin was also investigated for its potential immunomodulatory and anti-inflammatory effects. Severe acute COVID-19 and Long COVID are both characterized by profound immune dysregulation and hyper-inflammation. In Long COVID, this chronic inflammatory state is thought to be a primary driver of symptoms like brain fog, joint pain, and systemic fatigue. You can learn more about this process in our article on Long COVID Immune Dysfunction: Why Your Immune System Stays Activated. Researchers hypothesized that ivermectin might help calm this overactive immune response.

Pharmacological studies suggest that ivermectin can inhibit the transcription of nuclear factor-κB (NF-κB), a potent intracellular protein complex that controls the production of inflammatory cytokines. By suppressing NF-κB, ivermectin has been shown in some animal models to decrease the production of highly inflammatory molecules, specifically TNF-alpha, IL-1β, and IL-6. Because elevated levels of these specific cytokines are frequently observed in patients with Long COVID, the drug's dual potential to act as both an antiviral and an anti-inflammatory agent made it a highly attractive candidate for clinical trials.

Despite these promising theoretical mechanisms, a major pharmacological hurdle quickly emerged regarding the drug's concentration. In early 2020, a landmark in vitro (test tube) study by Caly et al. showed that a single dose of ivermectin could reduce SARS-CoV-2 viral RNA by 99.8% within 48 hours in monkey kidney cell lines. However, achieving this profound antiviral effect required a drug concentration of 5 micromolar (μM). This specific data point became the crux of the scientific debate surrounding the drug's viability.

The problem is that a concentration of 5 μM is approximately 35 to 50 times higher than the maximum plasma concentration a human can safely achieve using the standard, FDA-approved dosing of ivermectin. To reach the antiviral concentrations demonstrated in the petri dish, a patient would need to ingest highly toxic, potentially lethal doses of the medication. This fundamental disconnect between in vitro success and in vivo (in the living body) reality is a common challenge in drug development. It highlighted the critical need for large-scale human clinical trials to determine if the safe, standard doses of ivermectin could actually provide any clinical benefit for COVID-19 or Long COVID.

To definitively answer whether ivermectin's theoretical mechanisms translated into real-world benefits, major research institutions and government bodies funded massive, randomized, placebo-controlled "platform trials." These are the gold standard of medical research, designed to eliminate bias and provide clear, actionable data. One of the largest was the ACTIV-6 trial, funded by the NIH and conducted by the Duke Clinical Research Institute. This trial evaluated repurposed medicines in non-hospitalized adults with mild-to-moderate COVID-19, explicitly testing both lower and higher doses of ivermectin to ensure the drug was given a fair chance to succeed.

The ACTIV-6 results were unequivocal: neither the lower dose (400 μg/kg for 3 days) nor the higher dose (600 μg/kg for 6 days) provided any clinically significant benefit in resolving symptoms, preventing hospitalizations, or reducing emergency room visits compared to a placebo. The median time to sustained recovery was identical—11 days—for both the ivermectin and placebo groups. Similarly, the international TOGETHER trial, which evaluated high-risk patients primarily in Brazil, found no statistically significant difference in disease progression. Out of 1,500 patients in the ivermectin arm, the rates of hospitalization and extended ER observation were nearly identical to those receiving a placebo, leading the safety committee to halt the ivermectin arm for futility.

While ACTIV-6 and TOGETHER focused heavily on acute outcomes, the COVID-OUT trial, led by the University of Minnesota, was explicitly designed to investigate whether early outpatient treatment with repurposed drugs could prevent the development of Long COVID. This decentralized, quadruple-blind, phase 3 trial tracked over 1,100 adults for up to 10 months. It evaluated three medications: metformin, fluvoxamine, and ivermectin. The trial was highly anticipated by the Long COVID community, as it aimed to provide concrete data on prevention strategies.

The COVID-OUT findings were striking. While the trial proved that the diabetes drug metformin significantly reduced the risk of developing Long COVID, ivermectin showed zero efficacy in prevention. By day 300 of the study, the cumulative incidence of Long COVID was 7.7% in participants who received ivermectin, compared to 8.1% in those who received a matched placebo. This minor difference was not statistically significant, definitively showing that taking ivermectin during the acute phase of the virus does not protect a patient from developing Long COVID down the line.

To further evaluate the long-term impacts of the drug, Oxford University conducted the PRINCIPLE trial in the United Kingdom. This massive adaptive platform trial tracked participants at 3, 6, and 12 months post-infection, specifically measuring wellbeing, persistent symptoms, healthcare contacts, and time away from work. The goal was to see if ivermectin could alter the long-term trajectory of the disease, even if it didn't stop the acute infection immediately. This data is particularly relevant for patients already suffering from the prolonged effects of the virus.

Published in the Journal of Infection, the PRINCIPLE trial data concluded that ivermectin is highly unlikely to provide any clinically meaningful improvement in sustained recovery or Long COVID symptoms. The researchers formally stated that further trials of ivermectin in vaccinated community populations are unwarranted. The global medical and scientific consensus, strongly supported by ACTIV-6, TOGETHER, COVID-OUT, and PRINCIPLE, is that ivermectin has no role in the prevention or treatment of acute COVID-19 or Long COVID.

Given this overwhelming consensus from major trials, many patients wonder why there were so many positive reports about ivermectin early in the pandemic. The discrepancy lies in the difference between observational studies and randomized controlled trials (RCTs). Early on, many small, observational studies and anecdotal reports suggested that ivermectin was highly effective. However, these studies often suffered from significant methodological flaws, including small sample sizes, lack of placebo controls, and severe confounding variables. For example, patients receiving ivermectin in early hospital settings were often simultaneously receiving powerful corticosteroids like dexamethasone, making it impossible to attribute their recovery solely to ivermectin.

Furthermore, some of the most highly publicized early studies supporting ivermectin were later retracted due to data irregularities, ethical concerns, or outright fabrication. When the scientific community attempted to replicate these early positive findings using rigorous, double-blind, placebo-controlled methodologies—where neither the patient nor the doctor knows who is receiving the drug—the benefits vanished. This phenomenon underscores why the medical community relies on large-scale RCTs to establish treatment guidelines; they are designed specifically to filter out the noise, bias, and placebo effects that can make ineffective treatments appear successful in smaller, uncontrolled settings.

In its approved medical capacity, ivermectin is prescribed to treat specific parasitic infections like intestinal strongyloidiasis and onchocerciasis. For these conditions, the standard dosing is typically a single oral dose based on the patient's body weight, usually around 150 to 200 micrograms per kilogram (μg/kg). This single-dose regimen is highly effective for paralyzing and clearing parasites, and it is associated with a very strong safety profile. The drug is metabolized by the liver and excreted primarily in the feces, with a half-life of about 18 hours in humans.

However, the off-label protocols promoted for COVID-19 and Long COVID often recommended significantly higher doses taken over extended periods. Some alternative protocols suggested taking 400 to 600 μg/kg daily for 5 days, or even longer for chronic symptoms. As tested in the ACTIV-6 high-dose arm, even these elevated doses (600 μg/kg for 6 days) failed to produce clinical benefits. It is crucial to understand that increasing the dose of a medication does not magically change its mechanism of action against a virus; it merely increases the risk of reaching toxic concentrations in the body.

The fundamental issue with dosing ivermectin for viral infections lies in its pharmacokinetics—how the drug moves through the body. As discussed earlier, laboratory studies indicated that a concentration of 5 μM was required to achieve a 99% reduction in viral RNA. Pharmacological modeling has shown that even if a patient were to take a dose 10 times higher than the FDA-approved limit, the drug would still not reach the necessary antiviral concentrations in the lung tissue or the central nervous system. The human body simply cannot absorb and distribute the drug in a way that matches the conditions of a petri dish.

Furthermore, ivermectin is highly protein-bound in the blood, meaning that about 93% of the drug attaches to plasma proteins, leaving only a small fraction "free" and active to interact with tissues. This high protein binding further limits the drug's ability to penetrate the deep tissue reservoirs where SARS-CoV-2 viral persistence is theorized to occur. Therefore, regardless of the dosing schedule or administration timing, the physical limitations of human pharmacology prevent ivermectin from acting as an effective antiviral agent in vivo.

Because major medical organizations and pharmacies rightly restricted the dispensing of ivermectin for COVID-19 based on the lack of clinical evidence, some desperate patients turned to unregulated sources. This included purchasing veterinary formulations of the drug, such as horse paste or cattle pour-on solutions. These veterinary products are highly concentrated and formulated for animals that weigh well over a thousand pounds. They also contain inactive ingredients that have not been evaluated for safety in humans.

Ingesting veterinary formulations of ivermectin is incredibly dangerous and has led to numerous hospitalizations and calls to poison control centers. The FDA has issued multiple strong warnings against using animal medications for human conditions. Even when sourcing human-grade ivermectin from unregulated online pharmacies, patients risk receiving counterfeit, contaminated, or incorrectly dosed medications. When managing a complex condition like Long COVID, introducing unregulated and potentially toxic substances into the body can severely exacerbate immune dysregulation and cause permanent organ damage.

When taken at standard, FDA-approved doses for parasitic infections, ivermectin is generally well-tolerated. The most common side effects are usually mild and transient. These can include dizziness, nausea, vomiting, diarrhea, and mild stomach pain. Some patients may also experience a minor skin rash or a slight increase in heart rate. In the context of treating parasites, these side effects are often the result of the body's inflammatory reaction to the dying parasites rather than a direct toxicity of the drug itself.

However, patients with Long COVID, particularly those with concurrent conditions like dysautonomia or Postural Orthostatic Tachycardia Syndrome (POTS), often have highly sensitive nervous and gastrointestinal systems. Even mild side effects like nausea or diarrhea can trigger severe symptom flares, dehydration, and worsening of autonomic dysfunction. For a patient already struggling with profound fatigue and systemic instability, introducing a medication that causes gastrointestinal distress without offering any proven clinical benefit is a significant and unnecessary risk.

The safety profile of ivermectin changes dramatically when it is taken at the high doses or extended durations often promoted in off-label COVID protocols. At toxic levels, ivermectin can cross the blood-brain barrier and interfere with the human central nervous system. Severe ivermectin toxicity can manifest as profound neurological symptoms, including confusion, ataxia (loss of coordination), hallucinations, seizures, and in extreme cases, coma or death. These neurological risks are particularly alarming for Long COVID patients who are already battling severe cognitive dysfunction and brain fog.

In addition to neurological toxicity, high doses of ivermectin can cause severe gastrointestinal damage and hepatotoxicity (liver damage). The liver is responsible for metabolizing the drug, and overwhelming it with high, continuous doses can lead to elevated liver enzymes and acute liver injury. Patients may also experience severe hypotension (dangerously low blood pressure), which can be life-threatening, especially for individuals with pre-existing cardiovascular or autonomic nervous system issues. The FDA and CDC have extensively documented these severe adverse events associated with ivermectin misuse during the pandemic.

Ivermectin is metabolized in the liver by the cytochrome P450 system, specifically the CYP3A4 enzyme. This means it can interact significantly with other medications that utilize the same metabolic pathway. Drugs that inhibit CYP3A4—such as certain statins, calcium channel blockers, and HIV protease inhibitors—can increase the concentration of ivermectin in the blood, raising the risk of toxicity even at standard doses. Conversely, drugs that induce CYP3A4 can decrease ivermectin levels, rendering it completely ineffective.

Furthermore, ivermectin can interact with blood thinners like warfarin, potentially increasing the risk of bleeding. Because many Long COVID patients take a complex regimen of medications and supplements to manage their multi-system symptoms, adding an off-label drug like ivermectin without strict medical supervision is highly dangerous. It is absolutely critical that patients consult their healthcare provider before starting, stopping, or changing any treatment, to ensure there are no dangerous contraindications with their current medical protocol.

Discussing off-label treatments or controversial medications with a healthcare provider can be intimidating, especially when you are living with a poorly understood condition like Long COVID. If you are interested in exploring the viral persistence hypothesis and potential antiviral treatments, it is helpful to frame the conversation around the underlying science rather than a specific, unproven drug. Start by expressing your understanding of the current research. You might say, "I've been reading about the viral persistence theory in Long COVID and how lingering viral fragments might be driving my inflammation. Can we discuss what evidence-based options exist for addressing this?"

By focusing on the mechanism (viral persistence) rather than a debunked treatment (ivermectin), you open the door to a collaborative, science-based discussion. Your provider can then guide you toward therapies that are currently being studied in legitimate clinical trials or discuss symptom management strategies that target the downstream effects of that inflammation. This approach shows your provider that you are informed, proactive, and committed to safe, evidence-based care.

When consulting your healthcare provider, come prepared with specific questions about managing your most debilitating symptoms. If your primary concern is the brain fog and cognitive dysfunction often associated with Long COVID inflammation, ask about targeted interventions. For example, you might inquire, "Are there specific anti-inflammatory protocols or supplements that have clinical backing for neuroinflammation?" You can also discuss options like Curcumin to support brain fog and inflammation, which has established mechanisms for supporting systemic health.

If you are interested in the latest antiviral research, ask your doctor about ongoing clinical trials. You might ask, "Are you aware of any clinical trials for newer antivirals, like Ensitrelvir, that I might qualify for?" or "What is the current consensus on using medications like Paxlovid for Long COVID?" A knowledgeable provider will be able to explain that while recent trials for extended Paxlovid courses have shown mixed or disappointing results for general Long COVID populations, research is rapidly evolving toward identifying specific patient "endotypes" who might benefit from targeted therapies. Always remember, consulting a healthcare provider before starting or stopping any treatment is a hard requirement for safely managing complex chronic illness.

It is entirely normal to feel a deep sense of grief and frustration when a highly publicized treatment like ivermectin is proven ineffective. When you are suffering daily, the loss of a potential "cure" can be devastating. It is important to communicate this emotional toll to your healthcare provider. A compassionate doctor will validate your frustration and acknowledge the immense difficulty of living with a condition that currently lacks a definitive, FDA-approved cure. They should work with you to focus on what can be managed right now.

If your provider is dismissive of your symptoms or refuses to engage in a thoughtful discussion about your treatment options, it may be time to seek a second opinion. Look for clinics or specialists who focus on complex chronic conditions, dysautonomia, or post-viral syndromes. These specialists are often more familiar with the latest research and are better equipped to offer comprehensive, empathetic care that focuses on improving your quality of life through proven symptom management strategies, pacing, and targeted therapeutics.

While the definitive clinical data shows that ivermectin is not the answer for Long COVID, this does not mean patients are without options. The path forward requires shifting focus away from unproven "miracle cures" and toward comprehensive, evidence-based symptom management. Long COVID is a complex, multi-system condition, and managing it successfully often requires a multi-disciplinary approach. This includes addressing autonomic nervous system dysfunction (like POTS), managing mast cell activation, and strictly adhering to pacing strategies to prevent post-exertional malaise (PEM).

Many patients find significant relief by targeting specific symptoms with proven interventions. For instance, optimizing hydration and sodium intake can drastically improve orthostatic intolerance, while specific antihistamine protocols can help stabilize mast cells and reduce systemic inflammation. Additionally, targeted nutritional support may help manage cognitive symptoms. For example, exploring supplements like O.N.E. Omega to help clear brain fog and support heart rate variability can be a part of a broader, provider-supervised management plan. The goal is not a rapid cure, but a steady, sustainable improvement in daily functioning and quality of life.

The failure of ivermectin—and the mixed results of recent Paxlovid trials—has not ended the search for Long COVID treatments; rather, it has refined it. The scientific community is now moving toward precision medicine. Researchers are recognizing that Long COVID is likely a collection of different sub-types or "endotypes." Future clinical trials, such as the PREVAIL-LC trial testing Ensitrelvir, are aiming to identify exactly which patients have active viral persistence and target antiviral therapies specifically to them, rather than applying a one-size-fits-all approach.

Furthermore, research is expanding beyond direct antivirals to explore treatments that address the downstream effects of the initial infection. This includes studying immunomodulators to calm autoimmune responses, therapies to address microclots and endothelial damage, and protocols to suppress other dormant viruses (like Epstein-Barr Virus) that may have been reactivated by COVID-19. The landscape of Long COVID research is vast and continuously evolving, offering genuine, science-backed hope for the future.

Navigating the complexities of Long COVID requires a medical team that understands the nuances of post-viral syndromes and stays current with the latest peer-reviewed research. At RTHM, we specialize in treating complex chronic conditions, including Long COVID, ME/CFS, POTS, and MCAS. Our approach is rooted in validating your experience, utilizing advanced diagnostics, and creating highly personalized, evidence-based management plans that prioritize your safety and quality of life. We focus on treatments that have demonstrated real clinical utility, helping you manage your symptoms effectively while the scientific community continues to search for definitive cures.

If you are struggling to manage your Long COVID symptoms and are looking for a compassionate, scientifically rigorous approach to your healthcare, we are here to help. Explore RTHM's comprehensive care options to learn how our specialized team can support your journey toward better health. Please remember, this article is for educational purposes only. Always consult your healthcare provider before starting, stopping, or changing any treatment, medication, or supplement regimen.